
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics is experiencing an increase in gross margins, leading to a revision in estimates for fiscal year 2026. With a higher share count and operating expenses, the company's stock price has decreased, but the multi-billion dollar market potential and opportunities for growth through acquisitions provide potential for high returns. However, there are risks, such as low visibility on revenues and the need for further financing to sustain growth.
Bears say
Vivos Therapeutics is a medical technology company that recently reported its 2025 financial results, showing a 16% increase in revenue, but also a higher than expected net loss. The company has faced challenges with provider attrition and has had to implement cost-saving measures, which could lead to improved operational efficiency. However, there are still risks to achieving the company's price target, including the need for additional capital and potential competition from other sleep apnea treatment options.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares